ProCE Banner Activity


CDK4/6 Inhibitors in HR+/HER2- Breast Cancer: Addressing Barriers to Their Optimal Use

Patient Simulation

The development and FDA approval of cyclin-dependent kinase (CDK)4/6 inhibitors has changed the treatment paradigm for patients with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative (HR+/HER2-) breast cancer in the settings of both early and advanced disease. In this interactive virtual patient simulation activity, healthcare professionals can explore evidence-based guidance for integrating CDK4/6 inhibitors into the management of HR+/HER2- breast cancer. This activity features 3 different patient case scenarios presenting opportunities to perform molecular testing, select and modify treatment, and manage treatment-related toxicities.

For a quick review of the key evidence before starting these patient simulations, please see the associated expert commentary and downloadable slideset.

Physician Assistants: maximum of 1.50 hours of AAPA Category 1 CME credits Registered Nurses: 1.50 Nursing contact hours, includes 1.50 hour of pharmacology credit

Released: September 16, 2022

Expiration: September 15, 2023

No longer available for credit.



Julia LaBarbera

Julia LaBarbera, MSN, RN, AGACNP-BC

  • Nurse Practitioner
    Division of Hematology/Oncology
    Department of Medicine
    University of California, Los Angeles
    Santa Monica, California

Provided by

Provided by the Practicing Clinicians Exchange

ProCE Banner


This activity is supported by an educational grant from Lilly.


Target Audience

Oncology NPs, PAs, and nurses

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Develop treatment approaches for the individualized use of CDK4/6 inhibitors for HR+/HER2- breast cancer

  • Use recommended strategies for identifying and managing toxicities associated with CDK4/6 inhibitors

  • Identify strategies and resources to support patient adherence to CDK4/6 inhibitor therapy


All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

Primary Author

Julia LaBarbera, MSN, RN, AGACNP-BC

  • Nurse Practitioner
    Division of Hematology/Oncology
    Department of Medicine
    University of California, Los Angeles
    Santa Monica, California

Julia LaBarbera, MSN, RN, AGACNP-BC: consultant/advisor/speaker: Biotheranostics.

None of the members of the Planning Committee or PCE staff have any relevant financial relationships to disclose.

Instructions for Credit

Participants wishing to earn CE/CME credit must:

  1. Complete the content in its entirety
  2. Relate the content material to the learning objectives
  3. Complete post-test and evaluation form

Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 67%.

The estimated time to complete this activity is 1.50 hours.

Release date: September 16, 2022
Expiration date: September 15, 2023


Patient Simulation

In this virtual simulation platform program, you will meet 3 patients with HR+/HER2-breast cancer. The program will have you proceed through your patient’s history, overview of the current situation, and physical exam. The + button enables you to obtain additional information by ordering laboratory values, imaging, and to make referrals. As the patient scenario warrants, add your recommendations for diagnosis, treatments, and follow-up with the + button. End your patient visit and schedule a follow-up. At each end-of-visit, you will see your progress in achieving the predetermined goals for the case. Each case will test your ability to diagnose and prescribe evidence-based recommendations to improve care.


The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.



Joint Accreditation Statement

Joint AccreditationIn support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

ANCC Credit Designation

Nursing contact hours: 1.50, which includes 1.50 hours of pharmacology credit

AAPA Credit Designation

Joint AccreditationPracticing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.50 AAPA Category 1 CME credits. Approval is valid until September 11, 2023. PAs should only claim credit commensurate with the extent of their participation.

PA course advisor: Jessica Garner, DMSc, PA-C, University of the Pacific, Sacramento, California

IPCE Credit Designation
IPCEThis activity was planned by and for the healthcare team, and learners will receive 1.50 Interprofessional Continuing Education (IPCE) credits for learning and change.

Additional Information

This program has been made available online.